Dave Nitesh
of
Biocon
joined us for
World Biosimilar Congress USA 2016
to discuss
what happens to biosimilars being developed under 505b (2)
.
Download this presentation
to understand more about:
-
Key features of 505b (2)
-
Key features of 351k (1, 2)
-
Products approved under 505b (2)
-
Path ahead for products under development
and
more
!
Get your copy
here
!
If you're interested in learning more about biosimilars being developed, join us for
World Biosimilar Congress USA 2017
, held
May 23-24
in
San Diego, CA
. This event is co-located with
Americas Antibody Congress
and
Cell Culture World Congress USA.